Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper session: Haematological malignancies

620O - CART-ddBCMA for multiple myeloma: Interim results from phase I study

Date

10 Sep 2022

Session

Proffered Paper session: Haematological malignancies

Topics

Cell-Based Therapy;  Immunotherapy

Tumour Site

Multiple Meyloma

Presenters

Matthew Frigault

Citation

Annals of Oncology (2022) 33 (suppl_7): S283-S294. 10.1016/annonc/annonc1055

Authors

M. Frigault1, J. Rosenblatt2, N. Raje1, D. Cook1, M. Gaballa3, E. Emmanuel-Alejandro1, C. Cornwell4, K. Banerjee5, A. Rotte4, C. Heery6, D. Avigan2, A. Jakubowiak7, M. Bishop7

Author affiliations

  • 1 Cancer Center, MGH - Massachusetts General Hospital, 02114 - Boston/US
  • 2 Cancer Center, Beth Israel Deaconess Medical Center, 02215 - Boston/US
  • 3 Cancer Center, Massachusetts General Hospital - Surgical Oncology Division, 02114 - Boston/US
  • 4 Clinical And Regulatory Affairs, Arcellx, Gaithersburg/US
  • 5 Clinical And Regulatory Affairs, Arcellx, 20878 - Gaithersburg/US
  • 6 Clinical Development Department, Arcellx, 20878 - Gaithersburg/US
  • 7 Cancer Center, University of Chicago Medicine, IL 60637 - Chicago/US
More

Resources

Login to access the resources on OncologyPRO.

Abstract 620O

Background

Chimeric Antigen Receptor (CAR) T cell therapies targeting B-cell maturation antigen (BCMA) have demonstrated benefit in patients (pts) with relapsed/refractory Multiple Myeloma (RRMM). CART-ddBCMA is an autologous anti-BCMA CAR T cell therapy that utilizes a novel, synthetic binding domain, called a D-Domain, instead of a typical scFv binder. The objective of this first-in-human trial is to assess the safety & efficacy of CART-ddBCMA.

Methods

This is a phase I, multi-center, open label, dose escalation trial for pts with RRMM who have received ≥3 regimens or are triple refractory. Lymphodepletion is given days -5 to -3 followed by CART-ddBCMA infusion on day 0. Dose escalation was performed at 100 (DL1) & 300 (DL2) x 106 (± 20%) CAR+T cells, followed by expansion of DL1. The primary outcome measure is incidence of adverse events (AEs), including dose-limiting toxicities. Additional outcome measures are ORR, CR rate, DoR, MRD (clonoSEQ), PFS & OS.

Results

As of Jan 25, 2022, 25 pts received CART-ddBCMA, with median age 66 (range: 44-76), after a median of 5 prior lines of therapy (3-16), including 10 (40%) with extramedullary disease (EMD). Median follow-up was 296 d (58-716 d). Overall, 25 pts (19 DL1; 6 DL2) were evaluable for safety & 24 (18 DL1; 6 DL2) for efficacy analysis. All pts experienced CRS, but only 1 pt (in DL2) had grade (G) 3 CRS. All other CRS cases were G≤2, with no cases of G≥3 CRS in DL1. Four pts experienced ICANS (2, G≤2; 2, G3), with 1 G3 case in each of DL1 (5%) & DL2 (17%). All cases resolved without sequalae with standard management. The ORR was 100%, sCR/CR rate 67% & ≥VGPR rate 88%. Conversion to CR/sCR was observed with longer follow-up, as late as month 9 in this trial, & 5 pts with PR /VGPR in the DL1 have <9 months follow-up, with 4 (of 4 evaluable) negative at ≥10-5 for MRD. Overall, 17/20 (85%) evaluable pts have achieved best MRD response of ≥10-5. Of the first 6 pts dosed in DL1, 4 (67%) continue in ongoing sCR beyond 18 months, including 3 with EMD. Median duration of response, PFS & OS were not evaluable at the time of data-cut because 19 of 24 evaluable pts (79%) remain in ongoing response.

Conclusions

CART-ddBCMA has demonstrated clinical activity, including 100% ORR & durable responses.

Clinical trial identification

NCT04155749.

Editorial acknowledgement

Legal entity responsible for the study

Arcellx.

Funding

Arcellx.

Disclosure

M. Frigault: Financial Interests, Personal, Other, Consultant: Celgene, Arcellx; Financial Interests, Personal, Research Grant: Novartis, Kite. J. Rosenblatt: Financial Interests, Personal, Other, Consultant: Attivare, Wolters Kluwer Health; Financial Interests, Personal, Research Grant: BMS. N. Raje: Financial Interests, Personal, Other, Consultant: Celgene. C. Cornwell: Financial Interests, Personal, Full or part-time Employment: Arcellx. K. Banerjee: Financial Interests, Personal, Full or part-time Employment: Arcellx. A. Rotte: Financial Interests, Personal, Full or part-time Employment: Arcellx. C. Heery: Financial Interests, Personal, Full or part-time Employment: Arcellx. D. Avigan: Financial Interests, Personal, Advisory Board: Celgene, Juno, Partner Tx, Karyopharm, BMS, Aviv MedTech, Takeda, Legend, Chugai; Financial Interests, Personal, Research Grant: Pharmacyclics, Kite; Financial Interests, Personal, Other, Consultant: Parexel. A. Jakubowiak: Financial Interests, Personal, Advisory Board: BMS, Celgene, Abbvie, Gracell, GSK, Janssen, Karyopharm, Amgen, Sanofi. M. Bishop: Financial Interests, Personal, Research Grant: Kite; Financial Interests, Personal, Invited Speaker: Incyte, BMS; Financial Interests, Personal, Member of the Board of Directors: Autolus, Novartis, CRISPR. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.